19-May-2021 - Eidgenössische Technische Hochschule Zürich (ETH Zürich)

The Achilles heel of the Coronavirus

Frameshifting as possible target for antiviral drug development

SARS-​CoV-2 is critically dependent on a special mechanism for the production of its proteins. A collaborative team led by a research group at ETH Zurich obtained molecular insights into this process and demonstrated that it can be inhibited by chemical compounds, thereby significantly reducing viral replication in infected cells.

Viruses require the resources of an infected cell to replicate and then infect further cells, and transfer to other individuals. One essential step in the viral life cycle is production of new viral proteins based on the instructions in the viral RNA genome. Based on these construction plans, the cell’s own protein synthesis machine, called the ribosome, produces the viral proteins.

In the absence of viral infection, the ribosome moves along the RNA in strictly defined steps, reading three letters of RNA at a time. This three-​letter code defines the corresponding amino acid that is being attached to the growing protein. It almost never happens that the ribosome slips one or two RNA letters forward or backward instead of following the regular three-​letter steps. When such a slip of the ribosome occurs, it is called “a frameshift,” and it leads to incorrect reading of the genetic code.

Frameshifting almost never happens in our cells. It would lead to dysfunctional cellular proteins; however, certain viruses, such as coronaviruses and HIV, depend on a frameshifting event to regulate levels of viral proteins. For example, SARS-​CoV-2 - the virus that causes COVID-​19 - is critically dependent on frameshifting promoted by an unusual and intricate fold in the viral RNA.

Therefore, since frameshifting is essential for the virus but it almost never happens in our organism, any compound that inhibits frameshifting by targeting this RNA fold could potentially be useful as a drug to combat infection. However, so far, there is no information on how the viral RNA interacts with the ribosome to promote frameshifting, which would be important for drug development.

Detailed image of an essential process for coronavirus replication

A team of researchers from ETH Zurich and the Universities of Bern, Lausanne and Cork (in Ireland) has for the first time managed to reveal the interactions between the viral genome and the ribosome during frameshifting. Their results have just been published in the journal Science.

Using sophisticated biochemical experiments, the researchers managed to capture the ribosome at the frameshifting site of the SARS-​CoV-2 RNA genome. They could then study this molecular complex using cryo-​electron microscopy.

The results provided a molecular description of the process at unprecedented detail and revealed a number of novel unanticipated features. The frameshifting event causes the usually dynamic ribosome machine to adopt a strained conformation, which helped provide one of the sharpest and most accurate images of a mammalian ribosome, visualized in the process of frameshifting while reading the information from the viral genome. The researchers then followed up on their structural findings with in vitro and in vivo experiments including exploring how this process can be targeted with chemical compounds. Nenad Ban, Professor for Molecular Biology at ETH Zurich and co-​author of the study, emphasizes that “The results presented here on SARS-​CoV-2 will also be useful for understanding the frameshifting mechanisms in other RNA viruses”.

Possible target for antiviral drug development

The dependence of SARS-​CoV-2 on this ribosomal frameshifting event could be used to develop antiviral drugs. Previous studies reported that several compounds are able to inhibit frameshifting in coronaviruses, however, this study now provides information about the effects of these compounds on levels of SARS-​CoV-2 in infected cells.

In their experiments, both compounds reduced viral replication by three to four orders of magnitude and were not toxic for the treated cells. However, one of the two reduced viral replication by inhibiting ribosomal frameshifting, while the other might act through a different mechanism. 

Although these compounds are currently not potent enough to be used as therapeutic drugs, this study demonstrates that inhibition of ribosomal frameshifting has a profound effect on viral replication, which paves the way for the development of better compounds. Due to the fact that all coronaviruses depend on this conserved frameshifting mechanism, a drug that targets this process may even be useful to treat infections by more distantly related coronaviruses. “Our future work will focus on understanding the cellular defense mechanisms that suppress viral frameshifting, as this could be useful for development of small compounds with similar activity,” says Ban.

Facts, background information, dossiers

  • SARS-CoV-2
  • coronaviruses
  • viral proteins
  • ribosomes
  • cryo-electron microscopy
  • RNA viruses

More about ETH Zürich

  • News

    High-precision frequency measurement

    Many scientific experiments require highly precise time measurements with the help of a clearly defined frequency. Now, a new approach allows the direct comparison of frequency measurements in the lab with the atomic clock in Bern, Switzerland. For many scientific experiments, today’s resea ... more

    Harnessing AI to discover new drugs inspired by nature

    Artificial intelligence (AI) is able to recognise the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens ... more

    Designing better antibody drugs with artificial intelligence

    Machine learning methods help to optimise the development of antibody drugs. This leads to active substances with improved properties, also with regard to tolerability in the body. Antibodies are not only produced by our immune cells to fight viruses and other pathogens in the body. For a f ... more

  • q&more articles

    Analysis in picoliter volumes

    Reducing time, costs and human resources: many basic as well as applied analytical and diagnostic challenges can be performed on lab-on-a-chip systems. They enable sample quantities to be reduced, work steps to be automated and completed in parallel, and are ideal for combination with highl ... more

    Investment for the Future

    This is a very particular concern and at the same time the demand placed annually on Dr. Irmgard Werner, who, as a lecturer at the ETH Zurich, supports around 65 pharmacy students in the 5th semester practical training in “pharmaceutical analysis”. With joy and enthusiasm for her subject sh ... more

  • Authors

    Prof. Dr. Petra S. Dittrich

    Petra Dittrich is an Associate Professor in the Department of Biosystems Science and Engineering at ETH Zurich (Switzerland). She studied chemistry at Bielefeld University and the University of Salamanca (Spain). After completing her doctoral studies at the Max Planck Institute for Biophysi ... more

    Dr. Felix Kurth

    Felix Kurth studied bioengineering at the Technical University Dortmund (Germany) and at the Royal Institute of Technology in Stockholm (Sweden). During his PhD studies at ETH Zurich (Switzerland), which he completed in 2015, he developed lab-on-a-chip systems and methods for quantifying me ... more

    Lucas Armbrecht

    Lucas Armbrecht studied microsystems technology at the University of Freiburg (Breisgau, Germany). During his master’s, he focused on sensors & actuators and lab-on-a-chip systems. Since June 2015, he is PhD student in the Bioanalytics Group at ETH Zurich (Switzerland). In his doctoral stud ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by: